Qexp-MDx CYP2C9 Genotyping Kit

Impact of CYP2C9 variants 

CYP2C9*2 and CYP2C9*3 are common reduced-function single nucleotide polymorphisms (SNP) variants involving C-to-T and A-to-C substitutions, respectively. These variants may decrease CYP2C9 enzymatic activity and affect the metabolism of drugs such as warfarin. CYP2C9 genotyping can help characterize individual drug metabolism profiles and support pharmacogenomics and personalized medicine applications.

Why are CYP2C9*2 and CYP2C9*3 important?

Individuals carrying one CYP2C9*2 or CYP2C9*3 variant allele have reduced enzymatic activity, which decreases the metabolism rate of drugs such as warfarin, making them more likely to accumulate in the body and increasing the risk of bleeding. Therefore, lower doses are generally recommended. Those carrying two variant alleles (e.g., *2/*2, *2/*3, or *3/*3 ) have markedly reduced enzymatic activity and require special caution when using warfarin. Since CYP2C9 genetic variations contribute to differences in drug metabolism, establishing a rapid and automated CYP2C9 genotyping workflow supports pharmacogenomics and personalized medicine applications.

2-STEP "Sample In, Result Out" Workflow within around 1.5 Hours